Brilinta 90 mg Tikagrelor Tablets In Pakistan \ MyTelestore.com

Brilinta 90mg Ticagrelor Tablets contain ticagrelor, a prescription antiplatelet medicine belonging to the P2Y12 platelet inhibitor class. It works by reducing platelet activation and aggregation, helping prevent the formation of harmful blood clots in patients who require antiplatelet therapy.

Ticagrelor is used in specific cardiovascular treatment settings, including acute coronary syndrome (ACS) and certain patients with a history of myocardial infarction. Treatment should be prescribed and monitored by a qualified healthcare professional.

Key Benefits & Medical Uses

• Antiplatelet Action: Helps reduce platelet activation and aggregation.
• Helps Prevent Blood Clots: Reduces the ability of platelets to contribute to harmful clot formation.
• Acute Coronary Syndrome: Used in appropriate patients with ACS as part of a cardiovascular treatment plan.
• Post-Heart-Attack Therapy: May be used for selected patients with a history of myocardial infarction according to the prescribed treatment regimen.
• 90mg Strength: Provides the commonly used 90mg ticagrelor tablet strength for appropriate treatment schedules.

How Brilinta Works

Ticagrelor is a reversible P2Y12 receptor antagonist. It inhibits platelet activation and aggregation by blocking P2Y12-mediated signaling. This reduces platelet responsiveness and helps lower the risk of thrombotic cardiovascular events in patients for whom ticagrelor is indicated.

Product Details

• Brand: Brilinta
• Active Ingredient: Ticagrelor
• Strength: 90mg
• Dosage Form: Film-coated tablet
• Medicine Class: Antiplatelet / P2Y12 inhibitor
• Category: Prescription cardiovascular medicine
• Route: Oral

Dosage & Administration

The dose and duration of Brilinta treatment depend on the patient's cardiovascular condition and the treatment plan prescribed by the healthcare professional.

For certain acute coronary syndrome regimens, 90mg twice daily is used during the first year following the acute event, usually together with low-dose aspirin when prescribed.

Swallow the tablet as directed. Do not stop Brilinta or change the dose without consulting your doctor.

Important Safety Information

The most important safety concern with ticagrelor is bleeding. Patients should seek medical attention for severe or uncontrolled bleeding, vomiting blood, blood in the stool or urine, or other signs of significant bleeding.

Ticagrelor may also cause shortness of breath (dyspnea).

Tell your doctor if you have:

• A history of bleeding
• Stomach ulcers
• Previous stroke or intracranial bleeding
• Liver problems
• Recent or planned surgery
• Other cardiovascular conditions

Inform your healthcare professional about all prescription medicines, over-the-counter medicines, vitamins, supplements, and herbal products you use.